In This Issue
Journal: Cancer Discovery (2023)

In This Issue| February 06 2023 In This Issue Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2023 American Association for Cancer Research2023American Association for Cancer Research Cancer Discov (2023) 13 (2): 247–249. https://doi.org/10.1158/2159-8290.CD-13-2-ITI Related Content This is a related article to: A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia This is a related article to: Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer This is a related article to: MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology View more This is a related article to: Bone Metastasis Initiation Is Coupled with Bone Remodeling through Osteogenic Differentiation of NG2+ Cells This is a related article to: Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition This is a related article to: Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies This is a related article to: Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity This is a related article to: Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma This is a related article to: OncoLoop: A Network-Based Precision Cancer Medicine Framework This is a related article to: Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity This is a related article to: Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability View less See also related A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid LeukemiarRNA 2′-O-Methylation Regulates Leukemic Self-renewal Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic CancerT Cells Boost the Antitumor Effects of KrasG12D Inhibition MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma PathologyGenomic Profiling of Circulating Multiple Myeloma Cells Bone Metastasis Initiation Is Coupled with Bone Remodeling through Osteogenic Differentiation of NG2+ CellsNG2+ Cells Couple Bone Remodeling with Metastasis Initiation Targeting UGCG Overcomes Resistance to Lysosomal Autophagy InhibitionTargeting UGCG-Dependent Lipid Remodeling in Cancer Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic MalignanciesHuman Bone Marrow Organoids for Modeling Hematopoiesis Cellular Senescence Is Immunogenic and Promotes Antitumor ImmunitySenescence Is Immunogenic and Promotes Antitumor Immunity Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma The Mechanism of MMRd Impacts Response to PD-1 Blockade OncoLoop: A Network-Based Precision Cancer Medicine FrameworkThe OncoLoop Framework For Precision Oncology Senescence Rewires Microenvironment Sensing to Facilitate Antitumor ImmunitySenescence Enhances Tumor Cell Sensitivity to Host IFNγ Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal VulnerabilityLipogenic Vulnerability Conferred by Mutant IDH1 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record February 6 2023 Citation In This Issue. Cancer Discov 1 February 2023; 13 (2): 247–249. https://doi.org/10.1158/2159-8290.CD-13-2-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with few therapeutic options. The majority of patients with PDAC harbor a mutation in the KRAS oncogene. Kemp and colleagues utilized a small-molecule inhibitor of KrasG12D, MRTX1133, and identified deep tumor regressions in multiple immune-competent PDAC models. Additionally, inhibition of KrasG12D remodeled the tumor microenvironment from an immune-suppressive to an immune-reactive state with increased infiltration of M1-like macrophages and cytotoxic T cells. These results provide preclinical evidence for the efficacy of KrasG12D inhibition in PDAC and suggest MRTX1133 has the potential for translation to the clinic. See article, p. 298. While tumors with mismatch-repair deficiency (MMRd) all have high mutation burdens, only a fraction of patients respond to PD-1 checkpoint blockade. In a cohort of patients receiving pembrolizumab for MMRd endometrial cancer, Chow, Michaels, and colleagues found that the underlying molecular mechanism of MMRd was associated with treatment... You do not currently have access to this content.